Human Interleukin-2 (IL-2) (Proleukin)

Protein / enzyme

Human Interleukin-2 (IL-2) (Proleukin) is one of 65 small molecule programs targeting Breast Cancer. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Chronic Spontaneous UrticariaActive, not recruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

Chronic Spontaneous UrticariaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adriamycin

GGynecologic Oncology Group

Preclinical

87 2

Gemzar

GGynecologic Oncology Group

Preclinical

22 3

DATROWAY

Daiichi Sankyo

Preclinical

4 4

MS Contin

Merck & Co.

Preclinical

2 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 7

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 8

Chantix

PPrism Pharmaceuticals

Preclinical

1 9

Avastin

Roche

Preclinical

4 10

Systemic Therapy

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1/2Not yet recruiting

Breast Cancer

NCT05821686

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Efficacy of Interleukin-2 in Triple Negative Breast Cancer

Not yet recruiting·NNova Scotia Health Authority·Phase 1/2·NCT05821686·10 enrolled

Chronic Spontaneous Urticaria1 trial

Interleukin-2 for Refractory Chronic Spontaneous Urticaria

Recruiting·SSecond Xiangya Hospital of Central South University·Phase 2/3·NCT06924762·124 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Human Interleukin-2 (IL-2) (Proleukin). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Human Interleukin-2 (IL-2) (Proleukin) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Human Interleukin-2 (IL-2) (Proleukin). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nova Scotia Health Authority company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Company: NNova Scotia Health Authority

Human Interleukin-2 (IL-2) (Proleukin)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Breast Cancer1 trial

Chronic Spontaneous Urticaria1 trial

References

Drug Info

Quick Facts

Related News